Nothing Special   »   [go: up one dir, main page]

ES2072875T3 - Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. - Google Patents

Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Info

Publication number
ES2072875T3
ES2072875T3 ES89112463T ES89112463T ES2072875T3 ES 2072875 T3 ES2072875 T3 ES 2072875T3 ES 89112463 T ES89112463 T ES 89112463T ES 89112463 T ES89112463 T ES 89112463T ES 2072875 T3 ES2072875 T3 ES 2072875T3
Authority
ES
Spain
Prior art keywords
treatment
vip
male impotence
conjugates
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89112463T
Other languages
English (en)
Inventor
Illana Gozes
Matityahu Fridkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2072875T3 publication Critical patent/ES2072875T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN COMPOSICIONES FARMACEUTICAS PARA LA APLICACION TRANSDERMICA TOPICA PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA Y COMPOSICIONES PARA EL TRATAMIENTO DEL ASMA Y LA HIPERTENSION. LOS INGREDIENTES ACTIVOS DE TALES COMPOSICIONES SON SELECCIONADOS ENTRE EL PEPTIDO INSTESTINAL VASOACTIVO (VIP) DERIVADAS EFECTIVOS DEL MISMO Y FRAGMENTO EFECTIVOS DEL MISMO. EN LAS COMPOSICIONES PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA ES USADO UN CONJUGADO TRANSDERMICAMENTE EFECTIVO DEL VIP. SUS DERIVADOS O FRAGMENTOS ACOPLADOS A UNA PARTE HIDROFOBICA.
ES89112463T 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. Expired - Lifetime ES2072875T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8705588A IL87055A (en) 1988-07-08 1988-07-08 Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
ES2072875T3 true ES2072875T3 (es) 1995-08-01

Family

ID=11059032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89112463T Expired - Lifetime ES2072875T3 (es) 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Country Status (7)

Country Link
US (1) US5147855A (es)
EP (1) EP0354992B1 (es)
JP (1) JP2682702B2 (es)
AT (1) ATE120091T1 (es)
DE (1) DE68921814T2 (es)
ES (1) ES2072875T3 (es)
IL (1) IL87055A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
NZ237899A (en) * 1990-04-25 1997-03-24 Vivus Inc Substituted For Alza An apparatus comprising a shaft and a therapeutic composition; suitable to treat erectile dysfunction by insertion in the urethra
ATE101619T1 (de) * 1990-06-26 1994-03-15 Sanwa Kagaku Kenkyusho Co Vip-analogen und ihre verwendung.
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
IL99924A (en) * 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them
EP0618927A4 (en) * 1991-12-10 1995-05-24 Tanox Biosystems Inc CYTOKINE WITH AN UNPAIRED CYSTEIN REST AND CONJUGATES OF IT.
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5382392A (en) * 1993-02-05 1995-01-17 Alliedsignal Inc. Process for fabrication of carbon fiber-reinforced carbon composite material
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
WO1999002147A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
EP1409519A1 (en) * 2000-07-31 2004-04-21 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
CA2428552A1 (en) 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
RU2589255C2 (ru) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
EP3256151B1 (en) 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
FR2308266A1 (fr) * 1975-04-18 1976-11-12 Telecommunications Sa Procede de transmission dans des reseaux de connexion temporels a grande capacite
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
JPS56128721A (en) * 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
JPS61118399A (ja) * 1984-11-14 1986-06-05 Otsuka Pharmaceut Co Ltd ペプチドホルモンの製造法
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62135407A (ja) * 1985-12-10 1987-06-18 Meiji Seika Kaisha Ltd 育毛剤
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
SE8702520D0 (sv) * 1987-06-16 1987-06-16 Kabigen Ab Mammal intestine hormone precursor
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides

Also Published As

Publication number Publication date
US5147855A (en) 1992-09-15
ATE120091T1 (de) 1995-04-15
IL87055A (en) 1994-06-24
IL87055A0 (en) 1988-12-30
EP0354992A2 (en) 1990-02-21
DE68921814T2 (de) 1995-09-28
EP0354992A3 (en) 1991-01-16
DE68921814D1 (de) 1995-04-27
JPH0276821A (ja) 1990-03-16
JP2682702B2 (ja) 1997-11-26
EP0354992B1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
ES2072875T3 (es) Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.
EP0206291A3 (en) Sprayable pharmaceutical preparation for topical application
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
BR9407250A (pt) Uso de uma droga tendo atividade vasodilatadora para a fabricação de um medicamento para administração transmucosal transdérmica intranasal e retal
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
YU46978B (sh) Postupak za dobijanje preparata za nazalnu upotrebu
IT1224795B (it) Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
HK1000283A1 (en) New derivatives of non-steroidal anti-inflammatory anaggesic and/or antipyretic substances their use and pharmaceutical formulations containg them
EP0177342A3 (en) Oral formulation of therapeutic proteins
IT8848558A0 (it) Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
DE69026269D1 (de) Bioadhäsive zusammensetzung und pflaster
IL78061A (en) Pharmaceutical compositions based on simethicone and guar gum for protection of the oesogastroduodenal mucous membrane
ES2061828T3 (es) Composiciones antiirritantes y desensibilizadoras y metodos para su uso.
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
ES2052922T3 (es) Nucleosidos terapeuticos.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
ATE204752T1 (de) Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
IT8748117A0 (it) Derivati di glicina quali agenti preventivi e terapeutici per le complicanze diabetiche
EP0385909A3 (en) A kit or composition for the prevention or treatment of HIV-1 infections
DK68388A (da) Anvendelse af oxochinazolinderivater til fremstilling af laegemidler til behandling af hyperurikaemi
MX9303985A (es) Nucleosidos terapeuticos.
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 354992

Country of ref document: ES